Debby Van Dam

List of Publications by Citations

123 papers	4,805 citations	35 h-index	67 g-index
127 ext. papers	5,443 ext. citations	4.8 avg, IF	5.74 L-index

#	Paper	IF	Citations
123	The Glymphatic Hypothesis of Glaucoma: A Unifying Concept Incorporating Vascular, Biomechanical, and Biochemical Aspects of the Disease. *BioMed Research International*, **2017**, 2017, 5123148	3	1029
122	Decreased expression of the GABAA receptor in fragile X syndrome. *Brain Research*, **2006**, 1121, 238-45	3.7	250
121	Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. *European Journal of Neuroscience*, **2003**, 17, 388-96	3.5	197
120	Drug discovery in dementia: the role of rodent models. *Nature Reviews Drug Discovery*, **2006**, 5, 956-70	64.1	158
119	Animal models in the drug discovery pipeline for Alzheimer's disease. *British Journal of Pharmacology*, **2011**, 164, 1285-300	8.6	140
118	Immune hyperreactivity of Aβ plaque-associated microglia in Alzheimer's disease. *Neurobiology of Aging*, **2017**, 55, 115-122	5.6	132
117	Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. *Molecular Therapy*, **2010**, 18, 44-53	11.7	128
116	Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice. *Behavioural Brain Research*, **2000**, 117, 127-36	3.4	116
115	Increased White Matter Inflammation in Aging- and Alzheimer's Disease Brain. *Frontiers in Molecular Neuroscience*, **2017**, 10, 206	6.1	101
114	Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. *Psychopharmacology*, **2005**, 180, 177-90	4.7	100
113	Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). *Behavioural Brain Research*, **2005**, 162, 233-9	3.4	99
112	Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice. *Journal of Pathology*, **2012**, 228, 67-76	9.4	92
111	Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. *Behavioural Brain Research*, **2012**, 229, 244-9	3.4	89
110	Region- and age-specific changes in glutamate transport in the APP23 mouse model for Alzheimer's disease. *Journal of Alzheimer's Disease*, **2011**, 24, 287-300	4.3	77
109	Effect of Morris water maze diameter on visual-spatial learning in different mouse strains. *Neurobiology of Learning and Memory*, **2006**, 85, 164-72	3.1	73
108	Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy. *Human Molecular Genetics*, **2006**, 15, 53-64	5.6	71
107	Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. *European Journal of Neuroscience*, **2004**, 20, 2757-66	3.5	71

106	The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome. *Cell Cycle*, **2015**, 14, 2985-95	4.7	68
105	A new glaucoma hypothesis: a role of glymphatic system dysfunction. *Fluids and Barriers of the CNS*, **2015**, 12, 16	7	66
104	Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. *European Neuropsychopharmacology*, **2006**, 16, 59-69	1.2	63
103	Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?. *Cortex*, **2015**, 73, 36-61	3.8	62
102	Brain inflammation in a chronic epilepsy model: Evolving pattern of the translocator protein during epileptogenesis. *Neurobiology of Disease*, **2015**, 82, 526-539	7.5	57
101	PTZ-induced seizures in mice require a revised Racine scale. *Epilepsy and Behavior*, **2019**, 95, 51-55	3.2	54
100	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. *Neurobiology of Aging*, **2014**, 35, 2691-2700	5.6	52
99	Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease. *Neurobiology of Aging*, **2008**, 29, 241-52	5.6	48
98	APP23 mice as a model of Alzheimer's disease: an example of a transgenic approach to modeling a CNS disorder. *CNS Spectrums*, **2005**, 10, 207-22	1.8	46
97	Senescent changes in cerebrospinal fluid circulatory physiology and their role in the pathogenesis of normal-tension glaucoma. *American Journal of Ophthalmology*, **2013**, 156, 5-14.e2	4.9	45
96	Sleep and Alzheimer's disease: A pivotal role for the suprachiasmatic nucleus. *Sleep Medicine Reviews*, **2018**, 40, 17-27	10.2	45
95	Actigraphic measurement of agitated behaviour in dementia. *International Journal of Geriatric Psychiatry*, **2006**, 21, 388-93	3.9	44
94	Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease. *Journal of Alzheimerls Disease*, **2014**, 41, 819-33	4.3	43
93	Aripiprazole in the treatment of Alzheimer's disease. *Expert Opinion on Pharmacotherapy*, **2013**, 14, 459-74	4	39
92	Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model. *Behavioral Neuroscience*, **2008**, 122, 491-7	2.1	39
91	Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. *Neurochemistry International*, **2005**, 46, 409-22	4.4	38
90	Hyperactivity, neuromotor defects, and impaired learning and memory in a mouse model for metachromatic leukodystrophy. *Brain Research*, **2001**, 907, 35-43	3.7	38
89	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. *Current Alzheimer Research*, **2016**, 13, 1145-64	3	36

88	Non human primate models for Alzheimer's disease-related research and drug discovery. *Expert Opinion on Drug Discovery*, **2017**, 12, 187-200	6.2	34
87	The Glymphatic System: A New Player in Ocular Diseases? **2016**, 57, 5426-5427		33
86	Central administration of obestatin fails to show inhibitory effects on food and water intake in mice. *Regulatory Peptides*, **2009**, 156, 77-82		31
85	Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. *Psychopharmacology*, **2008**, 197, 37-43	4.7	31
84	Mood and male sexual behaviour in the APP23 model of Alzheimer's disease. *Behavioural Brain Research*, **2007**, 180, 146-51	3.4	31
83	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. *Alzheimer's Research and Therapy*, **2015**, 7, 7	9	30
82	Morphological changes in the enteric nervous system of aging and APP23 transgenic mice. *Brain Research*, **2011**, 1378, 43-53	3.7	30
81	Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissue. *Journal of Chromatography A*, **2014**, 1353, 28-39	4.5	29
80	Biochemical and behavioural phenotyping of a mouse model for GAMT deficiency. *Journal of the Neurological Sciences*, **2005**, 231, 49-55	3.2	29
79	Aggressive male APP23 mice modeling behavioral alterations in dementia. *Behavioral Neuroscience*, **2006**, 120, 1380-3	2.1	29
78	A multidisciplinary approach unravels early and persistent effects of X-ray exposure at the onset of prenatal neurogenesis. *Journal of Neurodevelopmental Disorders*, **2015**, 7, 3	4.6	26
77	Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI. *NeuroImage*, **2015**, 109, 151-9	7.9	26
76	Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome. *Journal of Alzheimer's Disease*, **2015**, 43, 871-91	4.3	25
75	Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2016**, 53, 1079-96	4.3	25
74	Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo. *Journal of Alzheimer's Disease*, **2018**, 65, 265-281	4.3	22
73	Increased Cerebrospinal Fluid Production as a Possible Mechanism Underlying Caffeine's Protective Effect against Alzheimer's Disease. *International Journal of Alzheimer's Disease*, **2011**, 2011, 617420	3.7	22
72	Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimer's Disease (AD) Brain Regions: Differential Findings in AD with and without Depression. *Journal of Alzheimer's Disease*, **2017**, 55, 763-776	4.3	22
71	Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes. *Frontiers in Neuroscience*, **2018**, 12, 185	5.1	19

70	Glaucoma considered as an imbalance between production and clearance of neurotoxins **2014**, 55, 5351-2		19
69	APP23 mice display working memory impairment in the plus-shaped water maze. *Neuroscience Letters*, **2006**, 407, 6-10	3.3	19
68	Neuroimaging of Subacute Brain Inflammation and Microstructural Changes Predicts Long-Term Functional Outcome after Experimental Traumatic Brain Injury. *Journal of Neurotrauma*, **2019**, 36, 768-788	5.4	18
67	Progressive Motor Deficit is Mediated by the Denervation of Neuromuscular Junctions and Axonal Degeneration in Transgenic Mice Expressing Mutant (P301S) Tau Protein. *Journal of Alzheimerls Disease*, **2017**, 60, S41-S57	4.3	17
66	Serum NGAL is Associated with Distinct Plasma Amyloid-Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome. *Journal of Alzheimerls Disease*, **2015**, 45, 733-43	4.3	17
65	Age-related macular degeneration, glaucoma and Alzheimers disease: amyloidogenic diseases with the same glymphatic background?. *Cellular and Molecular Life Sciences*, **2016**, 73, 4299-4301	10.3	16
64	Alzheimers disease: Neurotransmitters of the sleep-wake cycle. *Neuroscience and Biobehavioral Reviews*, **2019**, 105, 72-80	9	16
63	Comparison of extraction methods for peptidomics analysis of mouse brain tissue. *Journal of Neuroscience Methods*, **2011**, 197, 231-7	3	16
62	Excitatory amino acids and monoaminergic neurotransmitters in cerebrospinal fluid of acute ischemic stroke patients. *Neurochemistry International*, **2010**, 56, 865-70	4.4	15
61	Behavioural characterization of AnkyrinG deficient mice, a model for ANK3 related disorders. *Behavioural Brain Research*, **2017**, 328, 218-226	3.4	14
60	Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method. *MethodsX*, **2015**, 2, 112-23	1.9	14
59	Evaluation of the APP23-model for Alzheimers disease in the odour paired-associate test for hippocampus-dependent memory. *Behavioural Brain Research*, **2008**, 190, 147-51	3.4	14
58	Accelerated high-frequency repetitive transcranial magnetic stimulation enhances motor activity in rats. *Neuroscience*, **2017**, 347, 103-110	3.9	13
57	Impaired gait pattern as a sensitive tool to assess hypoxic brain damage in a novel mouse model of atherosclerotic plaque rupture. *Physiology and Behavior*, **2015**, 139, 397-402	3.5	13
56	Cerebrospinal fluid and serum MHPG improve Alzheimers disease versus dementia with Lewy bodies differential diagnosis. *Alzheimerls and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 172-181	5.2	13
55	GSA: behavioral, histological, electrophysiological and neurochemical effects. *Physiology and Behavior*, **2005**, 84, 251-64	3.5	13
54	Neuropeptides in Alzheimers disease: from pathophysiological mechanisms to therapeutic opportunities. *Current Alzheimer Research*, **2013**, 10, 449-68	3	13
53	Age-dependent changes in noradrenergic locus coeruleus system in wild-type and APP23 transgenic mice. *Neuroscience Letters*, **2009**, 463, 93-7	3.3	12

52	A behavioural study of neuroglobin-overexpressing mice under normoxic and hypoxic conditions. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2013**, 1834, 1764-71	4	11
51	Specific Triazine Herbicides Induce Amyloid-β42 Production. *Journal of Alzheimer's Disease*, **2016**, 54, 1593-1605	4.3	11
50	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. *Journal of Parkinson's Disease*, **2018**, 8, 71-84	5.3	10
49	Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models. *Neurobiology of Disease*, **2017**, 105, 235-244	7.5	10
48	Genes involved in cerebrospinal fluid production as candidate genes for late-onset Alzheimer's disease: a hypothesis. *Journal of Neurogenetics*, **2011**, 25, 195-200	1.6	10
47	Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis. *Vascular Pharmacology*, **2019**, 113, 70-76	5.9	10
46	Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability and reduces myocardial infarction in mice. *Vascular Pharmacology*, **2019**, 118-119, 106561	5.9	9
45	Aging, microglia and cytoskeletal regulation are key factors in the pathological evolution of the APP23 mouse model for Alzheimer's disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2017**, 1863, 395-405	6.9	9
44	Fast circulation of cerebrospinal fluid: an alternative perspective on the protective role of high intracranial pressure in ocular hypertension. *Australasian journal of optometry, The*, **2016**, 99, 213-8	2.7	9
43	Sleep architecture changes in the APP23 mouse model manifest at onset of cognitive deficits. *Behavioural Brain Research*, **2019**, 373, 112089	3.4	8
42	Glaucoma and the Role of Cerebrospinal Fluid Dynamics **2015**, 56, 6630-1		8
41	Late age increase in soluble amyloid-beta levels in the APP23 mouse model despite steady-state levels of amyloid-beta-producing proteins. *Biochimica Et Biophysica Acta - Molecular Basis of Disease* , **2016**, 1862, 105-12	6.9	8
40	The First Histologic Evidence of a Paravascular Pathway Within the Optic Nerve **2018**, 59, 1717		8
39	The role of low intracranial pressure in the development of glaucoma in patients with Alzheimer's disease. *Progress in Retinal and Eye Research*, **2014**, 39, 107-8	20.5	7
38	Intracranial pressure fluctuations: a potential risk factor for glaucoma?. *Acta Ophthalmologica*, **2015** , 93, e83-4	3.7	7
37	Pentylenetetrazole-induced Seizure Susceptibility in the Tau58/4 Transgenic Mouse Model of Tauopathy. *Neuroscience*, **2020**, 425, 112-122	3.9	7
36	Intracranial pressure and glaucoma: Is there a new therapeutic perspective on the horizon?. *Medical Hypotheses*, **2018**, 118, 98-102	3.8	7
35	Alzheimer's disease and glaucoma: can glymphatic system dysfunction underlie their comorbidity?. *Acta Ophthalmologica*, **2017**, 95, e244-e245	3.7	6

34	Adapted Morris Water Maze protocol to prevent interference from confounding motor deficits on cognitive functioning. *Somatosensory & Motor Research*, **2017**, 34, 172-178	1.2	6
33	Validation of the APP23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviour. *Arzneimittelforschung*, **2008**, 58, 265-8		6
32	Inflammation, Nitro-Oxidative Stress, Impaired Autophagy, and Insulin Resistance as a Mechanistic Convergence Between Arterial Stiffness and Alzheimer's Disease. *Frontiers in Molecular Biosciences*, **2021**, 8, 651215	5.6	6
31	Impaired hypoxic tolerance in APP23 mice: a dysregulation of neuroprotective globin levels. *FEBS Letters*, **2017**, 591, 1321-1332	3.8	5
30	Alzheimer's disease and glaucoma: Look-alike neurodegenerative diseases. *Alzheimer's and Dementia*, **2019**, 15, 600-601	1.2	5
29	Evaluating the applicability of mouse SINEs as an alternative normalization approach for RT-qPCR in brain tissue of the APP23 model for Alzheimer's disease. *Journal of Neuroscience Methods*, **2019**, 320, 128-137	3	5
28	The validation of Short Interspersed Nuclear Elements (SINEs) as a RT-qPCR normalization strategy in a rodent model for temporal lobe epilepsy. *PLoS ONE*, **2019**, 14, e0210567	3.7	5
27	Serum Corticosterone and Insulin Resistance as Early Biomarkers in the hAPP23 Overexpressing Mouse Model of Alzheimer's Disease. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
26	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation. *Journal of Alzheimer's Disease*, **2021**, 81, 1505-1527	4.3	5
25	Progressive tau aggregation does not alter functional brain network connectivity in seeded hTau.P301L mice. *Neurobiology of Disease*, **2020**, 143, 105011	7.5	4
24	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 99-111	5.2	4
23	5-HT receptors in Alzheimer's disease. *Neurochemistry International*, **2021**, 150, 105185	4.4	3
22	Do repetitive Valsalva maneuvers reduce glymphatic clearance?. *Annals of Neurology*, **2017**, 81, 322	9.4	2
21	Dilated Virchow-Robin spaces in primary open-angle glaucoma: a biomarker of glymphatic waste clearance dysfunction?. *Acta Radiologica Open*, **2016**, 5, 2058460116653630	1.2	2
20	Evidence for the existence of a communication between the eye and the brain?. *Acta Neurochirurgica*, **2017**, 159, 1413-1414	3	2
19	The two faces of the translaminar pressure difference: the biomechanical one and the biochemical one. *Australasian journal of optometry, The*, **2017**, 100, 102-103	2.7	2
18	Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils. *BMC Molecular and Cell Biology*, **2020**, 21, 81	2.7	2
17	A general decline in cerebrospinal fluid flow and optic nerve compartmentation: are these sequential steps leading to toxicity in normal-tension glaucoma?. *Acta Ophthalmologica*, **2016**, 94, e242-3	3.7	2

16	Fibromyalgia as a glymphatic overload syndrome. *Medical Hypotheses*, **2018**, 115, 17-18	3.8	1
15	Psychiatric Disorders in Dementia **2014**, 271-324		1
14	Age-related cognitive decline in spatial learning and memory of C57BL/6J mice. *Behavioural Brain Research*, **2022**, 418, 113649	3.4	1
13	The Role of Rodent Models in the Drug Discovery Pipeline for Dementia. *Neuromethods*, **2011**, 35-49	0.4	1
12	Altered stress hormone levels affect in vivo vascular function in the hAPP23 overexpressing mouse model of Alzheimer's disease. *American Journal of Physiology - Heart and Circulatory Physiology*, **2021**, 321, H905-H919	5.2	0
11	Cerebral and cerebellar language organization in a right-handed subject with a left temporal porencephalic cyst: An fMRI study. *Journal of Neurolinguistics*, **2016**, 37, 41-46	1.9	
10	Intrathecal cerebrospinal fluid infusion as a potential therapeutic strategy for Alzheimer's disease. *Medical Hypotheses*, **2019**, 122, 57	3.8	
9	"Hypodense Holes" and the Ocular Glymphatic System: Author Response: "Black Holes" and the Ocular Glymphatic System **2017**, 58, 1132-1133		
8	Letter to the Editor. Low ICP and normal tension glaucoma: optic nerve damage due to barotraumatic factors, failure of CSF dynamics, or both?. *Journal of Neurosurgery*, **2018**, 129, 1100-1103	3.2	
7	Animal Models for Brain Research **2014**, 3-46		
6	Behavioral Validation in Animal Models of Dementia. *Neuromethods*, **2011**, 143-154	0.4	
5	Animal Models for Brain Research **2021**, 3-55		
4	APP-Based Transgenic Models: The APP23 Model. *Neuromethods*, **2011**, 399-413	0.4	
3	General Introduction to Animal Models of Human Conditions. *Neuromethods*, **2011**, 3-13	0.4	
2	Species, Strain, and Gender Issues in the Development and Validation of Animal Models of Dementia. *Neuromethods*, **2011**, 53-75	0.4	
1	A General Decline in Cerebrospinal Fluid Flow: An Overlooked Risk Factor for Glaucoma?. *Journal of Neuro-Ophthalmology*, **2016**, 36, 227-8	2.6	